Recent Finacing
Recent Raise
ONL Therapeutics is a clinical-stage biopharmaceutical developing ONL1204, a small-molecule Fas inhibitor to prevent retinal cell death for retinal diseases, with ongoing Phase 1b and planned Phase 2 trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at ONL Therapeutics.
